General Information of Drug (ID: DMI96Y3)

Drug Name
PHT-427 Drug Info
Synonyms PHT 427; PHT427
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44240850
CAS Number
CAS 1191951-57-1
TTD Drug ID
DMI96Y3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AR-12 DM4RK6P Lymphoma 2A80-2A86 Phase 1 [3]
L-serine-O-phosphate DMTJ1NH Discovery agent N.A. Investigative [4]
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [5]
BX-912 DMZA45C Discovery agent N.A. Investigative [6]
BX-795 DMRIMLJ Discovery agent N.A. Investigative [6]
PF-5177624 DMUOFT0 Solid tumour/cancer 2A00-2F9Z Investigative [7]
GSK-2334470 DM3BI7R Solid tumour/cancer 2A00-2F9Z Investigative [8]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [5]
Akt inhibitor VIII DMDVIT1 Discovery agent N.A. Investigative [9]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphoinositide dependent protein kinase-1 (PDPK1) TT9QBI6 PDPK1_HUMAN Inhibitor [2]
RAC-beta serine/threonine-protein kinase (AKT2) TTH24WI AKT2_HUMAN Inhibitor [2]

References

1 Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem. 2009 Oct 1;17(19):6983-92.
2 Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
6 Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
7 Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
8 Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9.
9 Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.